Go to main content
R&D JW, leading global new drug development
Home

Pipeline

Our Pipeline at a Glance

28

Compounds in
Development

Disease Area

Cancer Immunological diseases Cardiovascular system and metabolic diseases Regenerative medicine Rare diseases Eye diseases Digestive system Nutrition ETC
In the Pipeline
Pre-Clinical Phase 1 Phase 2 Phase 3 Approval

Cancer

 WE
X
WE – Pre-Clinical
Mechanism of Action:
Wee/Myt1 dual inhibitor
Indications:
Partner:​
Additional Information:
Best-in-class
Substance Type:
 		JW2286
X
JW2286 – Phase 1
Mechanism of Action:
STAT3 inhibitor
Indications:
Partner:​
Additional Information:
First-in-class
Substance Type:
 		MOBILIA
(2024)
X
MOBILIA (2024) – Approval
Mechanism of Action:
CXCR4 antagonist
Indications:
Mobilization of hematopoietic stem cells into the peripheral blood for autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma
Storage:​
Store at room temperature (15–30°C) in a tightly closed container
Strength:​
Plerixafor 20mg/mL
Additional Information:
Hematopoietic stem cell mobilizing agent
Administration:
Subcutaneous injection (administer approximately 11 hours prior to initiation of hematopoietic stem cell collection)
Active Ingredient:
Plerixafor
Description:
Clear, colorless to pale yellow solution in a clear, colorless vial
DK

Immunological diseases

 SI
X
SI – Pre-Clinical
Mechanism of Action:
STAT6 inhibitor
Indications:
Partner:​
Additional Information:
Best-in-class
Substance Type:
 		TAVALISSE
(2025)
X
TAVALISSE(2025) – Approval
Mechanism of Action:
Spleen Tyrosine Kinase inhibitor
Indication:
Thrombocytopenia
Storage:
Store at room temperature (1–30°C) in a tightly closed container
Strength:
Fostamatinib Disodium Hexahydrate 189.3 mg
Additional Information:
First-in-class
Dosage and Administration:
100 mg orally twice daily (with or without food)
Active Ingredient:
Fostamatinib Disodium Hexahydrate
Description:
Light reddish-yellow, oval, film-coated tablet

Cardiovascular system and
metabolic diseases

 TP
X
TP – Pre-Clinical
Mechanism of Action:
TNIK, CSF1R dual inhibitor
Indications:
Partner:​
Additional Information:
First-in-class
Substance Type:
 		JW0110
X
JW0110 – Phase 1
Mechanism of Action:
Indications:
Diabetes and hyperlipidemia
Partner:​
Additional Information:
Modified new drug (fixed-dose combination)
Substance Type:
 		LIVALOZET HI
X
LIVALOZET HI – Phase 3
Mechanism of Action:
HMG-CoA reductase, Niemann-Pick C1 Like 1 Protein Blocker, Calcium channel blocker, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:​
Strength:​
2/10/80/5mg, 4/10/80/5mg, 2/10/160/5mg, 4/10/160/5mg, 4/10/160/10mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Pitavastatin, Ezetimibe, Amlodipine, Valsartan
Description:
 		LIVALO HI
(2025)
X
LIVALO HI(2025) – Approval
Mechanism of Action:
HMG-CoA reductase, Calcium channel blocker, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:​
Store at room temperature (1–30°C) in a tight container
Strength:​
2/80/5, 4/80/5, 2/160/5, 2/160/10, 4/160/5, 4/160/10mg
Additional Information:
Triple combination (fixed-dose combination)
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca / Valsartan / Amlodipine besylate
Description:
2/80/5, 4/80/5 mg: Round, film-coated tablet
2/160/5, 2/160/10, 4/160/5, 4/160/10mg: Oblong, film-coated tablet
TS
X
TS – Pre-Clinical
Mechanism of Action:
SGLT1/2 dual inhibitor
Indications:
Partner:​
Additional Information:
Best-in-class
Substance Type:
 		EMPA-GUARD
X
EMPA-GUARD – Phase 3
Mechanism of Action:
DPP4 inhibitor, SGLT2 inhibitor
Indications:
Type 2 diabetes mellitus
Partner:​
SKK
Additional Information:
Modified new drug, currently under NDA review
Substance Type:
Fixed-dose combination
 		LIVALO Z
(2021)
X
LIVALO Z(2021) – Approval
Mechanism of Action:
HMG-CoA reductase,
Niemann-Pick C1 Like 1 Protein Blocker
Indications:
Hyperlipidemia
Storage:​
Store at room temperature (1–30°C)
Strength:​
2/10, 4/10 mg
Additional Information:
Modified new drug (fixed-dose combination)
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca/Ezetimibe
Description:
Round, film-coated tablet
EPAMINURAD
X
EPAMINURAD – Phase 3
Mechanism of Action:
Urate anion exchanger 1 inhibitor
Indications:
Gout
Partner:​
Simcere Pharmaceutical
Additional Information:
Best-in-Class
Substance Type:
Synthetic new drug
 		LIVALO V
(2015)
X
LIVALO V(2015) – Approval
Mechanism of Action:
HMG-CoA reductase, Angiotensin-receptor blocker
Indications:
Hyperlipidemia, hypertension
Storage:​
Store at room temperature (1–30°C)
Strength:​
2/80, 4/80, 2/160, 4/160 mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Pitavastatin Ca/Valsartan
Description:
2/80, 4/80 mg: Round, film-coated tablet
2/160, 4/160 mg: Oblong, film-coated tablet
JDART
(2018)
X
JDART(2018) – Approval
Mechanism of Action:
5 α-reductase inhibitors
Indications:
Improvement and control of progression of symptoms of benign prostatic hyperplasia
Storage:​
Store in a tightly closed container at room temperature (1–30°C)
Strength:​
0.5mg
Additional Information:
Treatment of benign prostatic hyperplasia and male pattern hair loss
Administration:
One tablet orally once daily (swallow whole without chewing or splitting)
Active Ingredient:
Dutasteride
Description:
Light yellow, oval film-coated tablet

Regenerative medicine

 JW0061
X
JW0061 – Phase 1
Mechanism of Action:
GFRA1 agonist
Indications:
Alopecia
Partner:​
Additional Information:
First-in-class
Substance Type:
Synthetic new drug

Rare diseases

 ND
X
ND – Pre-Clinical
Mechanism of Action:
CDK5/CCND2 inhibitor
Indications:
Partner:​
Additional Information:
First-in-class
Substance Type:
 		HEMLIBRA
(2024)
X
HEMLIBRA(2024) – Approval
Mechanism of Action:
Bispecific monoclonal antibody that binds coagulation factors IX and X and mimics the function of activated factor VIII
Indications:
Routine prophylaxis to reduce or prevent bleeding episodes in patients with hemophilia A (factor VIII deficiency), with or without factor VIII inhibitors
Storage:​
Store in a tightly closed container at 2–8°C, protected from light
Strength:​
30mg/mL, 60mg/0.4mL, 105mg/0.7mL, 150mg/mL
Additional Information:
Non-factor therapy
Administration:
Subcutaneous injection (maintenance dosing once weekly, once every 2 weeks, or once every 4 weeks)
Active Ingredient:
Emicizumab
Description:
Colorless to pale yellow solution in a clear, colorless vial

Eye diseases

 JW1601
X
JW1601 – Pre-Clinical
Mechanism of Action:
H4R inhibitor
Indications:
Eye diseases
Partner:​
Additional Information:
First-in-class
Substance Type:

Digestive system

 RABEKHAN DUO
(2024)
X
RABEKHAN DUO(2024) – Approval
Mechanism of Action:
Indications:
Gastric ulcer, duodenal ulcer, gastroesophageal reflux disease (GERD), and maintenance therapy
Storage:​
Store in a tight container at room temperature (1–30°C)
Strength:​
10/700, 20/700 mg
Additional Information:
Fixed-dose combination
Administration:
Orally once daily
Active Ingredient:
Rabeprazole Sodium / Sodium Bicarbonate
Description:
Oval, film-coated tablet (color varies by strength, e.g., light yellow, light pink)

Nutrition

 JNT WINUF
(2013)
X
WINUF(2013) – Approval
Mechanism of Action:
Provides four lipid components including high-strength fish oil, along with glucose, amino acids, and electrolytes to maintain nutritional balance and exert anti-inflammatory effects
Indications:
Parenteral nutrition for patients in whom oral or enteral intake is impossible, insufficient, or contraindicated (provides amino acids, carbohydrates, lipids, and electrolytes)
Storage:​
Store in a tightly closed container at room temperature (1–25°C)
Strength:​
Varies by product line (362 mL, 725 mL, 1085 mL, 1450 mL, 2170 mL, etc.)
Additional Information:
3-chamber bag parenteral nutrition (omega-3–containing TPN)
Administration:
Intravenous injection
Active Ingredient:
Purified fish oil, purified soybean oil, medium-chain triglycerides (MCT), purified olive oil, amino acids, glucose, electrolytes, etc
Description:
Injection in a transparent three-chamber plastic bag containing a clear, colorless to pale yellow solution (glucose, amino acids) and a white emulsion (lipids)
WINUF A+
(2023)
X
WINUF A+(2023) – Approval
Mechanism of Action:
Promotes muscle synthesis and improves patients’ nutritional status by supplying high-dose amino acids and taurine, four types of lipids (including omega-3), glucose, and electrolytes
Indications:
Provides parenteral nutrition to patients who cannot receive, tolerate, or are contraindicated for oral or enteral nutrition, especially critically ill or postoperative patients requiring high protein
Storage:​
Store in a sealed container at room temperature (1–30°C)
Strength:​
Varies by product line (central venous: 1,000/1,500/2,000 mL; peripheral venous: 725/1,085/1,450 mL, etc.)
Additional Information:
High-amino-acid 3-chamber bag parenteral nutrition (with taurine)
Administration:
Intravenous injection (Winuf A Plus: central venous administration / Winuf A Plus Peri: peripheral venous administration)
Active Ingredient:
Refined fish oil, refined soybean oil, medium-chain triglycerides (MCT), refined olive oil, amino acids, glucose, electrolytes, taurine
Description:
Injection in a transparent plastic bag divided into three chambers, containing a colorless to pale yellow clear solution (glucose, amino acids) and a white lipid emulsion

ETC

 LINZAGOLIX
X
LINZAGOLIX – Phase 3
Mechanism of Action:
GnRH antagonist
Indications:
Bleeding caused by uterine fibroids
Partner:​
Kissei
Additional Information:
Substance Type:
Synthetic new drug
 		ENAROY
(2022)
X
ENAROY(2022) – Approval
Mechanism of Action:
Hypoxia Inducible Factor-Prolyl Hydroxylase inhibitor
Indications:
Treatment of anemia in patients with chronic kidney disease (renal anemia)
Storage:​
Store in a tightly sealed container at room temperature (1–30°C)
Strength:​
1, 2, 4 mg
Additional Information:
Oral treatment for renal anemia (new drug)
Administration:
Orally once daily
Active Ingredient:
Enarodustat
Description:
Round film-coated tablet (color varies by strength, including very light yellow, light orange, and light red)
TENOFECTION
(2022)
X
TENOFECTION(2022) – Approval
Mechanism of Action:
HBV DNA polymerase inhibitor
Indications:
Treatment of chronic hepatitis B
Storage:​
Store in a tightly closed container at room temperature (1–30°C)
Strength:​
300 mg
Additional Information:
Administration:
Orally once daily
Active Ingredient:
Tenofovir Disoproxil Phosphate
Description:
Light blue, almond-shaped film-coated tablet
X
Cancer
JW’s vision in anti-cancer therapies is to change the paradigm of cancer treatment and improve the quality of life for cancer patients.

To this end, JW is focusing on the research and development of targeted anticancer and immune cell therapies.

Beginning with the first development of dendritic cell-based immune cell therapies in metastatic renal cell carcinoma, JW has increased its understanding of immuno-oncology through differentiated clinical development programs for a variety of carcinomas.

JW is also continuing to research biomarkers to predict which patients will benefit the most from anticancer and immune cell therapies.

In addition to the immuno-oncology portfolio, JW is investigating the signaling mechanisms involved in cancer development and developing a cancer treatment portfolio, specifically targeting Wnt and STAT signaling systems.
X
Cardiovascular system and metabolic diseases
Cardiovascular disease includes any disease related to the heart or blood vessels.

JW is looking for a treatment that can improve cardiovascular management, focusing on hyperlipidemia and hypertension for patients who are threatened with life due to cardiovascular and metabolic diseases.

JW is also committed to ultimately improving quality of life and addressing unmet medical needs.

Livalo (component name pitavastatin) has been shown to be a safe treatment without the risk of diabetes, as it not only lowers the incidence of major cardiac events but also improves blood glucose control in clinical trials in Korean patients with acute infarction.

In addition, JW is developing various fixed-dose combination products using its technology to allow the patients with hyperlipidemia and hypertension to take the necessary drugs at once, and to increase the convenience of administration.

JW is currently working on the discovery of new therapies for the treatment of metabolic diseases based on molecular-level mechanisms.
X
Immunological diseases
JW continues to develop its expertise in immunology and is striving to develop innovative medicines for patients with diseases such as atopy, gout, asthma and idiopathic pulmonary fibrosis.

JW's goal is to develop treatments that act on the molecular level to solve the root causes of chronic inflammatory diseases not managed by conventional symptom-relieving therapies.
X
Regenerative medicine
Regenerative medicine is the field of medicine that replaces or regenerates human cells, tissues and organs to restore their original function.

JW's goal is to regenerate damaged areas by activating the body's own recovery mechanisms of previously unrecoverable tissues and organs.

JW is particularly interested in Wnt signals, which are involved in stem cell growth, differentiation and related signaling pathways, and is working on the development of therapeutics applicable to hair follicle regeneration, muscle and brain diseases, etc.
X
Rare diseases
Rare disease is defined as a disease in which rare population is less than 20,000 or difficult to diagnose due to rare disease management law.

JW is working to develop effective therapies for patients with rare diseases including hemophilia.
X
Eye diseases
Vision decline is a major health and social problem affecting more than one billion people around the world. Potentially limiting social interaction and independence, it affects patients' ability to work and leads to the development of depression and anxiety.

JW is currently working on the discovery of new therapies for the treatment of diseases such as Diabetic retinopathy (DR) and age-related macular degeneration (AMD) based on molecular-level mechanisms.
X
Diagnose
JWBS-R001, Phase 1
Novel biomarker for sepsis diagnosis
  • WRS, Tryptophanyl tRNA synthetase (53KDa)
  • Rapidly secret upon infection to prime innate immunity
  • WRS is a reliable, specific and sensitive biomarker for sepsis
    (Ahn YH et al., Nature Microbiology, 2016)
POCT
  • Central lab quality at the point of care.
  • Quantitative measurement of 6 analyses in parallel.
  • A fully automatic immunoassay analyzer with chemiluminescence technology.
  • The data within less than 20 minutes.
Patent
  • Composition and method for detecting a diagnostic marker for sepsis using tryptophanyl-tRNA synthetase (2016. 03. 02)
  • Antibodies specifically binding to WRS protein and uses thereof (2019. 07. 18)
JWBS-R002, Preclinical
Novel biomarker for pancreatic cancer diagnosis
  • CFB, Complement factor B (93KDa)
  • A combination of CFB and CA19-9 improved diagnostic accuracy of pancreatic cancer
  • The world’s first multi-biomarker diagnostic kit with which pancreatic cancer.
Patent
  • Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer (2014. 05. 12)
X
Nutrition
WINUF
  • Indication : Nutritional Nutrition
  • Ingredient : Dextrin/Amino acid/Lipid emulsion, 3 Chamber system
  • Volume : 1085mL, 1435 mL, 1820mL, 1450mL, 2020mL
  • Packing material : Non-PVC plastic bag
Everamin injection
  • Indication : Nutritional Nutrition
  • Ingredient : amino acid (glycine, arginine, isoleucine, etc.)
  • Volume : 100/250mL
  • Packing material : Non-PVC plastic bag
Acetapen injection
  • Indication : Pain and fever
  • Ingredient : Acetaminophen 10mg
  • Volume : 100mL
  • Packing material : Non-PVC plastic bag
Levetiram injection
  • Indication : Anticonvulsants
  • Ingredient : Levitracetam 1000mg
  • Volume : 110mL
  • Packing material : Non-PVC plastic bag